88 28. 29.
30.
31. 32.
33.
34.
35. 36.
37.
38.
39.
40. 41.
42.
43. 44.
45. 46. 47. 48.
49.
50.
51. 52. 53.
Peptídeos Vasoativos e o Rim
SIRAGY, H.M. AT1 and AT2 receptors in the kidney: role in disease and treatment. Am. J. Kidney Dis., 36 (Suppl. 1):S4-S9, 2000. TSUTSUMI, Y.; MATSUBARA, H.; MUSAKI, H. Angiotensin II type 2 receptor expression activates the vascular kinin system and causes vasodilation. J. Clin. Invest., 104:925-935, 1999. RUIZ-ORTEGA, M.; LORENZO, O.; EGIDO, J. Angiotensin III upregulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts. Kidney Int., 54 (Suppl. 68):S41-S45, 1998. MOELLER, I.; ALLEN, A.M.; CHAI, S-Y.; MENDELSON, F.A.O. Bioactive angiotensin peptides. J. Human Hypertens., 12:289-293, 1998. ROCHA E SILVA, M.; BERALDO, W.T.; ROSENFELD, G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globin by snake venoms and by trypsin. Am. J. Physiol., 156:261-273, 1949. MARGOLIUS, H.S. Kallikrein-kinin system. In: Textbook of Nephrology, 3.ª edição, editado por Massry, S.G. e Glassock, R.J. Baltimore, Williams & Wilkins, pp. 203, 1995. BHOOLA, K.D.; FIGUEROA, C.D.; WORTHY, K. Bioregulation of kinins: kallikreins, kininogens, and kininase. Pharmacol. Rev., 44:180, 1992. SCICLI, A.G.; CARRETERO, O.A. Renal kallikrein-kinin system. Kidney Int., 29:120, 1986. URA, N.; CARRETERO, O.A.; ERDOS, E.G. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int., 32:507, 1987. NASJLETTI, A.; COLESSA-CHORERIO, J.; McGIFF, J.C. Disappearance of bradykinin in the renal circulation of dogs: Effects of kininase inhibition. Cir. Res., 37:59, 1975. CAMPBELL, D.J. Towards understanding the kallikrein-kinin system: insights from measurements of kinin peptides. Braz. J. Med. Biol. Res., 33:665-677, 2000. FIGUEROA, C.D.; MACLVER, A.G.; MACKENZIE, J.C.; BHOOLA, K.D. Localization of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry, 89:437, 1988. XIONG, W.; CHAO, L.; CHAO, J. Renal kallikrein mRNA localization by in situ hybridization. Kidney Int., 35:1324, 1989. CARRETERO, O.A.; SCICLI, A.G. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In: Hypertension: Pathophysiology, Diagnosis and Management, 2nd edition, edited by J.H. Laragh and B.M. Brenner. Raven Press, New York, pp. 983, 1995. BASCANDS, J.L.; PECHER, C.; ROUAUD, S.; EDMOND, C.; TACK, J.L.; BASTIE, M.J.; BURCH, R.; REGOLI, D.; GIROLAMI, J.P. Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am. J. Physiol., 264:F548, 1993. WEBSTER, M.E.; GILMORE, J.P. Influence of kallidin-10 on renal function. Am. J. Physiol., 206:714, 1964. GILL, J.R.; MELMON, K.L.; GILLESPIE, L.; BARTTER, F.C. Bradykinin and renal function in normal man: Effects of adrenergic blockade. Am. J. Physiol., 209:844, 1965. GRANGER, J.P.; HALL, J.E. Acute and chronic actions of bradykinin on renal function and arterial pressure. Am. J. Physiol., 248:F87, 1985. EDWARDS, R.M. Response of isolated renal arterioles to acetylcoline, dopamine and bradykinin. Am. J. Physiol., 248:F183, 1985. KAUKER, M.L. Bradykinin action on the efflux of luminal 22Na in the rat nephron. J. Pharmacol. Exp. Ther., 214:119, 1980. BEIERWALTES, W.H.; SCHRYVER, S.; SANDERS, E. Renin release selectively stimulated by prostaglandin PGI2 in isolated rat glomeruli. Am. J. Physiol., 243:F276, 1982. DeBOLD, A.J.; BORENSTEIN, H.B.; VERESS, A.T.; SONENBERG, A. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci., 28:89, 1981. BRENNER, B.M.; BALLERMANN, B.J.; GUNNING, M.E.; ZEIDEL, M.L. Diverse biological actions of atrial natriuretic peptide. Physiol. Rev., 70:665, 1990. COGAN, M.G. Atrial natriuretic peptide. Kidney Int., 37:1148, 1990. TANG, J.; FEI, H.; XIE, C.W. Characterization and localization of atriopeptin in rat atrium. Peptides, 5:1173, 1984. INAGAMI, T. Atrial natriuretic factor. J. Biol. Chem., 264:3043, 1989.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64. 65.
66.
67.
68.
69.
70.
71.
72.
73. 74.
75.
SUZUKI, T.; YAMAZAKI, T.; YAKAZI, Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc. Res., 51:489-494, 2001. LUFT, F.C.; LANG, R.E.; ARONOFF, G.R. Atriopeptin III kinetics and pharmacodynamics in normal and anephric rats. J. Pharmacol. Exp. Ther., 236:416, 1986. YANDLE, T.G.; RICHARDS, A.M.; NICHOLLS, M.G. Metabolic clearance rate and plasma half life of alpha human atrial natriuretic peptide in man. Life Science, 38:1827, 1986. YUKIMURA, T.; ITO, K.; TAKENAGA, T. Renal effects of synthetic human atrial natriuretic polypeptide in anesthetized dogs. Eur. J. Pharmacol., 103:363, 1984. FRIED, T.A.; McCOY, R.N.; OSGOOD, R.W.; STEIN, J.H. Effect of atriopeptin II on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am. J. Physiol., 250:F 1119, 1986. LIGHT, D.B.; SCHWIEBERT, E.M.; KARLSON, K.H.; STANTON, B.A. Atrial natriuretic peptide inhibits a caption channel in renal inner medullary collecting duct cells. Science, 243:383, 1989. OELKERS, W.; KLEINER, S.; BAHR, V. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin, and blood pressure in humans. Hypertension, 12:462, 1988. MAACK, T.; MARION, D.N.; CAMARGO, M.J. Effects of auriculin on blood pressure, renal function, and the renin-aldosterone system in dogs. Am. J. Medicine, 77:1069, 1984. OPGENORTH, T.J.; BURNETT, J.C. Jr.; GRANGER, J.P.; SCRIVEN, T.A. Effects of atrial natriuretic peptide on renin secretion in nonfiltering kidney. Am. J. Physiol., 250:F798, 1986. KURTZ, A.; DELLA BRUNA, R.D.; PFEILSCHIFTER, J. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc. Natl. Acad. Sci. USA, 83:4769, 1986. KUDO, T.; BAIRD, A. Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor. Nature, 312:756, 1984. LEWICKI, J.A.; PROTTER, A.A. Physiological studies of the natriuretic peptide family. In: Hypertension: Pathophysiology, Diagnosis and Management, 2nd edition, edited by J.H. Laragh and B.M. Brenner. Raven Press, New York, pp. 1029-1053, 1995. JANSSEN, W.M.T.; deJONG, P.E.; VAN DER HEM, G.K.; de ZEEUW, D. Effect of human atrial natriuretic peptide on blood pressure after sodium depletion in essential hypertension. Br. Med. J., 293:351, 1986. RICHARDS, A.M.; NICHOLLS, M.G.; ESPINER, E.A. Effects of alpha-human atrial natriuretic peptide in essential hypertension. Hypertension, 7:812, 1985. HILDEBRANDT, D.A.; BANKS, R.O. Effects of atrial natriuretic factor on renal function in rats with nephrotic syndrome. Am. J. Physiol., 254:F210,1988. ZIETSE, R.; SCHALEKAMP, M.A. Effect of synthetic human atrial natriuretic peptide (102-126) in nephrotic syndrome. Kidney Int., 34:717, 1988. FORSSMANN, W.G.; MEYER, M.; FORSSMANN, K. The renal urodilatin system: clinical implications. Cardiovasc. Res., 51:450-462, 2001. GUNNING, M.; BRENNER, B.M. Urodilatin. In: Hypertension: Pathophysiology, Diagnosis and Management, 2nd edition, edited by J.H. Laragh and B.M. Brenner. Raven Press, New York, pp. 1021-1027, 1995. YANAGISAWA, M.; KURIHARA, H.; KIMURA, S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332:411, 1988. RUBANYI, G.M.; BOTELHO, L.H.P. Endothelins. FASEB J., 5:2713, 1991. MARSDEN, P.A.; GOLIGORSKY, M.S.; BRENNER, B.M. Endothelial cell biology in relation to current concepts of vessel wall structure and function. J. Am. Soc. Nephrol., 1:931, 1991. LUSCHER, T.F.; BOCK, H.A.; YANG, Z.; DIEDERICH, D. Endothelin-derived relaxing and contracting factors: Perspectives in nephrology. Kidney Int., 39:575, 1991.